Neurochem Faces Obstacles To Making Supplement Out Of Drug Candidate
This article was originally published in The Tan Sheet
Executive Summary
Neurochem's plan to market a failed Alzheimer's disease drug candidate as a dietary supplement could stumble in the United States over requirements of the Dietary Supplement Health and Education Act, regulatory experts say
You may also be interested in...
Neurochem’s Supplement Launch In U.S. On Hold Due To DSHEA Question
Neurochem plans to launch a failed Alzheimer's drug candidate as a dietary supplement in Canada this year and in Europe and Japan in 2009, but has not determined whether it will make the product available in theU.S., company executives said Feb. 21
Neurochem’s Supplement Launch In U.S. On Hold Due To DSHEA Question
Neurochem plans to launch a failed Alzheimer's drug candidate as a dietary supplement in Canada this year and in Europe and Japan in 2009, but has not determined whether it will make the product available in theU.S., company executives said Feb. 21
Neurochem’s Supplement Launch In U.S. On Hold Due To DSHEA Question
Neurochem plans to launch a failed Alzheimer's drug candidate as a dietary supplement in Canada this year and in Europe and Japan in 2009, but has not determined whether it will make the product available in theU.S., company executives said Feb. 21